Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.
Focal therapy for prostate cancer has been increasingly utilized with the goal of effective disease control while maximizing patient functional outcomes. The optimal patient selection criteria are not known and therefore are not standardized. This review compares the available expert panel consensus guidelines with the selection criteria utilized in recently published focal therapy trials. Because the data from focal trials are still maturing, the currently enrolling clinical trials are reviewed as well. In addition, the recent literature regarding technological advances in prostate biopsy and imaging strategies are added to the current guidelines to recommend a rationale for patient selection.
Division of Urologic Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Michael R
MR
Abern
Matvey
M
Tsivian
Thomas J
TJ
Polascik
D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle; D003452:Cryosurgery / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D007150:Immunohistochemistry; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000379:methods; D009361:Neoplasm Invasiveness / Q000473:pathology; D018579:Patient Selection; D017410:Practice Guidelines as Topic / Q000592:standards*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D036761:Ultrasound, High-Intensity Focused, Transrectal / Q000379:methods
D017430:Prostate-Specific Antigen